| IN TR ODUC TION
Sotalol is a class III antiarrhythmic drug that combines potassium channel-blocking properties (thereby prolonging action potential duration) with nonselective b-adrenergic receptor blocking properties.
Sotalol is a commonly used PO antiarrhythmic drug for chronic management of ventricular arrhythmias in dogs. Orally administered sotalol also may be used to acutely terminate arrhythmias in dogs that are hemodynamically stable because of its rapid absorption, with peak plasma concentration likely to occur within 2-4 hours postpill. 1 Sotalol appears to be a well-tolerated and an effective treatment of ventricular arrhythmias in Boxers with familial ventricular arrhythmias, 2 and clinical experience suggests this is also true for other breeds.
Clinicians may hesitate to use sotalol in some situations. As with all b-adrenergic receptor antagonists, sotalol has negative inotropic properties, which raises concern over its use in dogs with systolic dysfunction or congestive heart failure. Systolic dysfunction may be present in dogs affected with ventricular arrhythmias secondary to, for example, arrhythmogenic right ventricular (RV) cardiomyopathy, dilated cardiomyopathy (DCM), tachycardia-induced cardiomyopathy, ischemia, or myocarditis.
However, in dogs, the negative inotropic effect of sotalol (because of bblockade) appears to be modest (ie, approximately one-fifth the negative inotropic effect of propranolol). 3 Also, 2 independent studies in healthy anesthetized dogs using invasive indices of left ventricular (LV) systolic function (1dP/dt) demonstrated that the negative inotropic effect of sotalol is attenuated or balanced by enhanced contractility secondary to prolonged action potential duration and hence, prolonged time for calcium entry. 4, 5 Based on these studies, the clinical impact of sotalol administration on systolic function in dogs with ventricular arrhythmias may be negligible, but has not yet been investigated.
Clinical experience suggests systolic dysfunction may be a common finding in dogs with ventricular arrhythmias. Systolic dysfunction may be secondary to primary cardiac disease or a tachyarrhythmia, as is the case with tachycardia-induced cardiomyopathy. 6 In primary cardiomyopathies such as preclinical DCM and arrhythmogenic RV cardiomyopathy, echocardiographic identification of LV or RV systolic dysfunction provides important diagnostic and prognostic information. [7] [8] [9] [10] [11] [12] [13] [14] Dogs affected by these diseases are also commonly affected by ventricular arrhythmias that may be managed with sotalol. Therefore, understanding the echocardiographic effects of sotalol on systolic function in dogs with ventricular arrhythmias could provide clinically useful information.
The objective of our study was to determine the effect of a single PO dose of sotalol on several echocardiographic indices of RV and LV systolic function in dogs with ventricular arrhythmias. We hypothesized that a single PO dose of sotalol would minimally decrease echocardiographic indices of ventricular systolic function.
| M A TE RI A L S A ND M E TH ODS
The Institutional Animal Care and Use Committee at the University of California, Davis (protocol #18482) approved all procedures in our study. Owner consent for participation in the study was obtained for each dog before enrollment.
| Animals
Study subjects were client-owned dogs that presented to the Cardiology Service at the University of California, Davis Veterinary Medical
Teaching Hospital for evaluation of cardiac disease or were referred for the purpose of the study. Dogs were enrolled consecutively over a 30-month period if they were diagnosed with a ventricular arrhythmia and were deemed to be hemodynamically stable, weighed >10 kg (for PO sotalol dosing purposes), and were not currently taking any antiarrhythmic drugs or cardiac medications known to affect ventricular function.
Dogs were required to have a hemodynamically stable ventricular arrhythmia, defined for the purpose of our study as a ventricular arrhythmia for which urgent antiarrhythmic treatment was not deemed necessary by the attending board-certified veterinary cardiologist.
Dogs were excluded from the study if they required sedation to facilitate echocardiography, or if they were diagnosed with congestive heart failure.
| Study design
For the purpose of this prospective study, all dogs underwent a cardiovascular examination, a 6-lead ECG of 5 minutes duration, and a baseline echocardiogram. After the echocardiogram, dogs received sotalol 2-2.5 mg/kg PO once, rounded to the nearest one-quarter of an 80 or 120 mg tablet (Sotalol hydrochloride tablets, Apotex Inc, Toronto, Ontario, Canada; sotalol group). Dogs received a single PO dose of sotalol for the purpose of the study and not necessarily because it was clinically indicated (ie, the study served as a pharmacodynamic study
and not a therapeutic trial). Two-to-four hours postpill, dogs underwent a 2nd ECG and echocardiogram. This time point was selected because peak absorption of sotalol in dogs has been shown to occur within 2-4 hours after PO administration. 1 Time from sotalol administration to the post-sotalol echocardiogram was recorded. Dogs were monitored after the administration of sotalol until discharged to the client, which concluded the study. Sotalol was continued at the discretion of the attending clinician. 
| Statistical analysis
Statistical analyses were performed using a commercial software pack- 
| RE SUL TS
A total of 35 dogs were enrolled in our study, 27 in the sotalol group and 8 in the control group. Within the sotalol group, mean (SD) age Eight dogs were enrolled in the control group, and a summary of their electrocardiographic and echocardiographic data is presented in Table 2 . Mean (SD) age was 10.4 (1.9) years. Body weight was 29.7 Normally distributed data presented as mean (SD). a Non-normally distributed data presented as median (interquartile range).
Abbreviations: LVIDs_N, left ventricular internal dimension at end-systole normalized to bodyweight; LV EF, left ventricular ejection fraction; LV FS, left ventricular shortening fraction; LV SA, left ventricular shortening area; RV S', peak systolic RV myocardial velocity at the lateral tricuspid annulus; TAPSE_N, tricuspid annular plane systolic excursion normalized to bodyweight; VPC, ventricular premature complex. Bolded P-values denote statistical significance (Bonferroni corrected P < .008). Normally distributed data presented as mean (SD). a Non-normally distributed data presented as median (interquartile range). In humans, considerable clinical evidence documents PO sotalol's lack of effect on systolic function (LV EF determined by radionuclide angiography) in the majority of cases. [24] [25] [26] [27] However, most of these studies evaluated LV EF after more long-term treatment, which could explain the differences in our findings. Interestingly, one of the previously mentioned invasive studies in dogs 5 noted a similar significant decrease in systolic function (LV 1dP/dt) after the 1st dose of sotalol when compared with baseline. After repeated dosing, however, systolic function increased and was not significantly different from baseline.
The authors attributed this initial effect to sotalol's b-blocking properties and the later increase in systolic function to an increase in intracellular calcium concentration. 5 Given these findings and the results of our study, dose titration of sotalol may be ideal, particularly in dogs with decreased systolic function, as has been advocated by some. 28 Several of the dogs in our study were diagnosed with systolic dysfunction, including 9 (33%) with LV systolic dysfunction (5 of which had LA enlargement), 7 (26%) with RV systolic dysfunction, and 3 (11%) with both. None of the dogs in our study experienced any adverse effects, including overt signs of low cardiac output or congestion, secondary to sotalol administration during the monitoring period.
However, the short-term nature of our study design and lack of objective monitoring criteria (eg, heart rate with continuous ECG, respiratory
rate, blood pressure) should be emphasized, and these results should be interpreted with caution. One study evaluating sotalol's antiarrhythmic effect in Boxers with ventricular arrhythmias showed that sotalol was well tolerated when administered for 21-28 days. 2 However, results of systolic function assessment were not reported.
Our study showed that a single PO dose of sotalol significantly decreases sinus heart rate, number of VPCs/5-minutes, and arrhythmia severity grade 2-4 hours post-sotalol as assessed by a 5-minutes ECG.
A proarrhythmic effect of sotalol was not identified by the 5-minutes ECG post-sotalol. These results agree with a study 2 evaluating the more long-term antiarrhythmic effects of sotalol in Boxers with ventricular arrhythmias using 24-hours Holter monitor analysis in which a lack of a proarrhythmic effect and decreases in average heart rate, VPCs/24 hours, and arrhythmia grade also were documented. However, because of the relative insensitivity of 5-minutes ECGs, 29 a more robust ECG assessment (ie, 24-hours ambulatory ECG) is necessary to confirm our findings and more accurately judge the effectiveness of sotalol on ventricular ectopy in our patient population.
Our study had several limitations, including the relatively few number of dogs in our control group, a lack of a gold standard to assess systolic function (also discussed above) and the short-term nature of our study design based on a single PO dose of sotalol. In addition, the dogs that made up our study sample were affected by a variety of diseases (known or unknown) associated with ventricular arrhythmias. This represents a limitation of our study design insomuch as our results cannot be directly translated to a single disease entity such as preclinical DCM of the Doberman pinscher. Our findings cannot necessarily be extrapolated to dogs being treated with sotalol chronically or when the drug has reached steady state. Our study design mandated that the post-sotalol evaluations were performed during a narrow range of time (2-4 hours postpill). Drug concentrations of sotalol were not measured to evaluate differences in drug absorption or patient metabolism. In addition, we did not determine if the dogs in our study were affected by a b-adrenergic receptor polymorphism. 30 These polymorphisms have been shown to impact heart rate response to atenolol in healthy dogs, and, as such, their possible role in our patient population is unknown. 31 Despite the possibility of a mild decrease in ventricular systolic function, a single PO dose of sotalol appears to be well tolerated, even in dogs with left atrial enlargement or systolic dysfunction because no adverse effects were noted during the study period. Additional longer-term studies with a larger number of controls would be ideal to confirm our findings.
